Advanced Search

Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2014 October;55(5) > The Journal of Cardiovascular Surgery 2014 October;55(5):631-40

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE JOURNAL OF CARDIOVASCULAR SURGERY

A Journal on Cardiac, Vascular and Thoracic Surgery


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632

 

The Journal of Cardiovascular Surgery 2014 October;55(5):631-40

LATEST DEVELOPMENTS IN THE TREATMENT OF CRITICAL LIMB ISCHEMIA 

Antiplatelet therapy in critical limb ischemia: update on clopidogrel and cilostazol

Spiliopoulos S.

Department of Interventional Radiology, Patras University Hospital, Patras, Greece

Antiplatelet therapy is essential for critical limb ischemia (CLI) patients, both as primary prevention for ischemic events and as adjuvant pharmacotherapy in order to avoid acute or late thrombo-occlusive events and maintain patency following peripheral endovascular or open surgical limb-salvage revascularization procedures. According to currently updated international guidelines clopidogrel as monotherapy or as part of dual antiplatelet therapy is recommended in CLI patients, while recent evidence delineated the beneficial effect of cilostazol in patients undergoing peripheral endovascular angioplasty or stenting as its administration resulted in a decrease of restenosis and clinically-driven reinterventions, as well as in the enhancement of platelet inhibition. This review aims in discussing recent evidence on the topic of antiplatelet therapy in CLI patients, with a special focus on the use of clopidogrel and cilostazol.

language: English


FULL TEXT  REPRINTS

top of page